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A Phase 2 Study of Galunisertib (TGF-b1Receptor Type I
Inhibitor) and Sorafenib in Patients With Advanced
Hepatocellular Carcinoma
R.K. Kelley, MD1, E. Gane, MD2, E. Assenat, MD3, J. Siebler, MD4, P.R. Galle, MD5, P. Merle, MD6, I.O. Hourmand, MD7,
A. Cleverly, MSc8, Y. Zhao, MD9, I. Gueorguieva, PhD8, M. Lahn, MD9, S. Faivre, MD10, K.A. Benhadji, MD9
and G. Giannelli, MD11
INTRODUCTION: Inhibition of tumor growth factor-b (TGF-b) receptor type I potentiated the activity of sorafenib in
preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective
inhibitor of TGF-b1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC
treatment.
METHODS: The combination of galunisertib and sorafenib (400mgBID) was tested in patients with advanced HCC
and Child-Pugh A liver function without prior systemic therapy. Galunisertib dose was administered 80
or 150 mg b.i.d. orally for 14 days every 28 days in safety lead-in cohorts; in the expansion cohort, all
patients received galunisertib 150mgb.i.d. Objectives included time-to-tumor progression, changes in
circulating alpha fetoprotein and TGF-b1, safety, overall survival (OS), response rate, and
pharmacokinetics (PK).
RESULTS: Patients (n5 47) were enrolled from 5 non-Asian countries; 3 and 44 patients received the 80 mg
and 150 mg b.i.d. doses of galunisertib, respectively. The pharmacokinetics and safety profiles
were consistent with monotherapy of each drug. For the 150 mg b.i.d. galunisertib cohort, the
median time-to-tumor progression was 4.1 months; the median OS was 18.8 months. A partial
response was seen in 2 patients, stable disease in 21, and progressive disease in 13. TGF-b1
responders (decrease of >20% from baseline) vs nonresponders had longer OS (22.8 vs 12.0
months, P 5 0.038).
DISCUSSION: The combination of galunisertib and sorafenib showed acceptable safety and a prolonged OS
outcome.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A55, http://links.lww.com/CTG/A56, and http://links.lww.com/CTG/A57
Clinical and Translational Gastroenterology 2019;10:e-00056. https://doi.org/10.14309/ctg.0000000000000056
INTRODUCTION
Hepatocellular carcinoma (HCC) is the predominant form of
primary liver cancer, which was the second most common cause
of global cancer mortality in 2012 (1). In the United States,
mortality from liver cancer is rising faster than from any other
cancer (2). HCC is associated with chronic liver diseases such as
hepatitis B or C virus infection, nonalcoholic fatty liver disease,
alcoholic liver disease, and cirrhosis. HCC is most often
diagnosed at a late stage, when surgical treatment is no longer an
option and systemic therapy is minimally effective. Sorafenib,
a multikinase inhibitor approved in 2007 for liver cancer, is the
first-line standard-of-care for patients with advanced Barcelona
Clinic Liver Cancer stage C HCC or intermediate Barcelona
Clinic Liver Cancer stage B HCC noneligible or after failure of
chemoembolization (3). In randomized studies of advancedHCC
patients with Child-Pugh A liver function, sorafenib was
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associated with improved survival compared to placebo in both
a Western population in the SHARP trial (overall survival [OS]
10.7 vs 7.9 months, hazard ratio 0.69) and a predominantly Asian
hepatitis B virus-positive population (OS 6.5 vs 4.2 months,
hazard ratio 0.68) (4,5). After progression on sorafenib, regor-
afenib, cabozantinib, and ramucirumab have improved survival
in phase 3 trials (6–8). Recent studies of PD-1 immune check-
point inhibitors in HCC have demonstrated prolonged, durable
responses, leading to regulatory approval in the United States
(9,10). In the front-line setting for advanced HCC, the multi-
kinase inhibitor, lenvatinib, demonstrated noninferiority to sor-
afenib in the REFLECT trial (11), but multiple drugs and
combination regimens have failed to improve upon the outcomes
of sorafenib monotherapy (12).
Tumor growth factor-b (TGF-b) is a secreted cytokine that
acts as a paracrine tumor promotor in advanced, metastatic
cancer (13). TGF-b is a master regulating molecule triggering
(i) the epithelial-mesenchymal transition through E-cadherin
downregulation (14), (ii) neoangiogenesis by increasing pro-
duction of the vascular endothelial growth factor (15), (iii) in-
vasion by b1 integrin activation (16), and (iv) altering the
tumor/host interaction upregulating connective tissue growth
factor production (17). These activities lead to HCC tumor
progression.
Galunisertib (LY2157299) is a small-molecule selective in-
hibitor of the TGF-b receptor type I (RI), a serine/threonine
kinase. TGF-b has been shown to be elevated in both serum and
tumor samples from patients with HCC (18,19), and TGF-b
signaling is associated with resistance to sorafenib in HCC cell
lines (20). In preclinical models of HCC, TGF-b inhibitors in-
cluding galunisertib reduce growth, invasion, and progression
(14–16,21). Galunisertib also has been studied in combination
with sorafenib in HCC cell lines and ex vivo tumor samples,
resulting in increased growth inhibition and apoptosis, and
underscoring a potential role for TGF-b inhibition in overcoming
sorafenib resistance (22). Thismay be explained by a recent report
that TGF-b signaling confers sorafenib resistance, and that
galunisertib enhanced sorafenib-induced apoptosis (20).
The pharmacokinetics (PK), pharmacodynamics, safety, and
efficacy of galunisertib have been evaluated in preclinical and
clinical phase 1 studies (23–27). An intermittent dosing strategy
of 14 days on, 14 days off, and a therapeutic window of 160–300
mg/dwere defined. No dose-limiting toxicities were observed and
galunisertib was well tolerated.
In a phase 2 study of second-line patients with HCC, galuni-
sertib showed clinical benefit in a subset of patients (28,29).
Median time-to-tumor progression (TTP) was 2.7 months (95%
confidence interval [CI]: 1.5–2.9) in patients with higher baseline
alpha fetoprotein (AFP, $1.53 upper limit of normal) plasma
levels and 4.2 months (95% CI: 1.7–5.5) in patients with lower
baseline AFP. Median OS was 7.3 months (95% CI: 4.9–10.5) in
patients with higher baseline AFP and 16.8 months (95% CI:
10.4–24.1) in patients with lower baseline AFP. The safety profile
of galunisertib in HCC was consistent with observations in other
tumor types. The most frequently occurring treatment-emergent
adverse events overall (.20% of patients) were fatigue (33.6%),
anemia (25.5%), peripheral edema (22.8%), and abdominal pain
(21.5%). The most common grade 3/4 treatment-related adverse
Table 1. Baseline demographics and disease characteristics
Galunisertib 150 mg b.i.d. 1
sorafenib 400 mg b.i.d.
N 5 44
Sex, male 39 (88.6)
Age, yr, median (range) 64 (36, 84)
Race
White 20 (45.5)
Native Hawaiian or other pacific
islander
7 (15.9)
Asian 6 (13.6)
Black or African American 2 (4.5)
Missing/other 9 (20.5)
ECOG performance status 0 36 (81.8)
ECOG performance status 1 8 (18.2)
Child-Pugh class (A), 5 pointsa 25 (56.8)
Child-Pugh class (A), 6 pointsa 19 (43.2)
TGF-b1, pg/mL, median (range) 1956 (495, 32,685)
AFP: ,200 ng/mL 24 (54.5)
AFP: 200–400 ng/mL 4 (9.1)
AFP: .400 ng/mL 16 (35.4)
Portal vein thrombosis 5 no 29 (65.9)
Portal vein thrombosis 5 yes 15 (34.1)
BCLC stage B 18 (40.9)
BCLC stage C 23 (52.3)
Tumor morphology (CLIP
classification)b
Uninodular and extension#50% 2 (4.5)
Multinodular and extension
#50%
33 (75.0)
Massive or extension .50% 9 (20.5)
Distant metastasis 35 (79.5)
Disease etiology
Hepatitis B 8 (18.2)
Hepatitis C 15 (34.1)
Nonalcoholic fatty liver disease
(hepatic steatosis)
3 (6.8)
Alcohol use 9 (20.5)
Other 3 (6.8)
Multiple 6 (13.6)
Prior locoregional therapy 20 (45.5)
Data are n (%) unless otherwise indicated. Table 1 does not include the 3
patients treated with galunisertib 80 mg b.i.d. dose.
AFP, alpha fetoprotein; BCLC, Barcelona-Clinic Liver Cancer; ECOG, Eastern
Cooperative Oncology Group.
aIn the Child-Pugh classification system, 5–6 points 5 class A.
bHepatology. 1998 Sep; 28(3):751–5.
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events were neutropenia (2.7%) and fatigue, anemia, increased
bilirubin, hypoalbuminemia, and embolism (1.3% each).
Based uponpreclinical evidence that galunisertib could augment
the efficacy of sorafenib, we conducted a phase 2 trial of galunisertib
in combination with sorafenib as the first line of systemic therapy
for advanced HCC in patients with Child-Pugh A liver function.
Here, we report the efficacy, safety, and AFP and TGF-b biomarker
results for this novel combination in advanced HCC.
METHODS
Subjects and study design
This was an open-label, multicenter, phase 2 study of
LY2152799 (galunisertib) in patients with HCC (Clinical-
Trials.gov: NCT01246986). The study had multiple parts;
reported here is part C, which evaluated galunisertib in
combination with sorafenib in patients with advanced HCC
who had not received prior systemic treatment (see Figure S1,
Supplementary Digital Content 1, http://links.lww.com/
CTG/A55). Galunisertib was administered orally at a dose of
80 or 150 mg b.i.d. in the safety lead-in cohort and 150 mg
b.i.d. in the expansion cohort, on days 1–14 in 28 day cycles.
All patients received sorafenib at the standard starting dose of
400 mg b.i.d. Sorafenib was adjusted based on previously
published guidelines (4).
Eligible patients were adults with a histologic diagnosis of
HCC not amenable to surgery, measurable disease by Response
Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, per-
formance status#1 on the Eastern Cooperative Oncology Group
Figure 1. Kaplan-Meier plots of TTP andOS: 150mg b.i.d. cohort. (a) TTP by RECIST v1.1. (b) TTP bymRECIST. (c) OS. CI, confidence interval; OS, overall
survival; RECIST, Response Evaluation Criteria in Solid Tumor; TTP, time-to-tumor progression.
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scale, adequate organ function including Child-Pugh A liver
function, and who had not received previous systemic therapy.
Patients with mixed histology or moderate or severe cardiac
diseasewere excluded.All patients provided informed consent for
participation in the study and before any study-specific proce-
dures. The protocol was approved by local ethical review boards
and was conducted according to the International Conference on
Harmonization Good Clinical Practice guidelines and the Dec-
laration of Helsinki.
OBJECTIVES
The primary objectives were to characterize the TTP by RECISTs
v1.1 (30) and the effect of treatment on the TGF-b associated
biomarkers AFP and TGF-b1 with the recommended dose of
galunisertib in combination with sorafenib. The secondary
objectives were to evaluate safety of the combination and the
effect of treatment on OS, progression-free survival, overall re-
sponse rate by RECIST 1.1 as well as modified RECIST (31)
(tumor assessment was performed every 6 weeks), and pop-
ulation PK of galunisertib in combination with sorafenib.
PK and biomarker methods
Plasma samples were analyzed for galunisertib using vali-
dated liquid chromatography-mass spectrometry/MS methods
(BPLY215A and BPLY215B). The lower limit and the upper limit
of quantification were 0.050 and 10.0 ng/mL for BPLY215A and
5.00 and 1,000 ng/mL for BPLY215B. AFP and TGF-b1 levels in
plasma were analyzed by ELISA (R&D Systems, DB100B,
Minneapolis, MN).
Statistical analyses
Part C of this study was designed to enroll approximately 40
first-line patients with HCC into 2 dose cohorts of galunisertib
in combination with standard dose sorafenib. Based upon the
acceptable safety profile of the higher dose of galunisertib of 150
mg b.i.d. in the safety lead-in cohort, all patients were enrolled
to the subsequent expansion cohort, in accordance with the
study design and after an interim safety analysis. All patients
who received at least 1 dose of study drug were evaluated for
safety. Patients with measurable disease at baseline were in-
cluded in summaries of tumor response. Time-to-event efficacy
endpoints (TTP and OS) were analyzed for patients treated at
150 mg b.i.d. For efficacy endpoints, no formal hypothesis
testing based on a priori power calculations was planned; rather
differences in various endpoints between appropriate sub-
groups were estimated.
MedianTTPand the secondary objective ofOSwere estimated
using the Kaplan-Meier method, with the log-rank tests to
compare distributions of TTP orOS between subgroups. TTPwas
measured from the date of first dose to the first date of objective
progression of disease. For each patient who was not known to
have had a progression of disease as of the data-inclusion cutoff
date for this analysis, or who died without progression of disease,
TTP was censored for the analysis at the date of the patient’s last
tumor assessment before that cutoff date. OS was measured from
the date of first dose to the date of death from any cause. For each
patient who was not known to have died as of the data inclusion
cutoff date for this analysis, OS duration was censored for the
analysis at the date of last prior contact.
Biomarker response was defined as .20% decrease in the
biomarker from baseline values at any time point, based upon
thresholds employed in previous studies (32). TTPwas compared
between biomarker subgroups at baseline (AFP$ 400 ng/mL vs
AFP , 400 ng/mL; TGF-b1 less than or greater than/equal to
median). TTP and OS were compared between biomarker res-
ponders and nonresponders postbaseline. All confidence inter-
vals of treatment effects are provided at a 2-sided alpha level of
0.05, unless otherwise stated. Statistical software used was SAS
version 9.2 or higher (SAS Institute, Cary, NC).
RESULTS
Twelve sites in 5 non-Asian countries (Germany, France, Italy,
NewZealand, and theUnited States) enrolled a total of 47 patients
between March 2013 and June 2015. Three patients in the safety
lead-in cohort received galunisertib at the lower dose of galuni-
sertib of 80 mg orally b.i.d. for 14 days every 28 days. After an
interim safety analysis of the first 3 patients, 44 patients
Table 2. Best overall response by the investigators
Galunisertib 300 mg/d 1 sorafenib,
N5 44
RECIST 1.1 mRECIST
Complete response 0 0
Partial response 2 (4.5) 5 (11.4)
Stable disease 21 (47.7) 13 (29.5)
Progressive disease 13 (29.5) 5 (11.4)
Not done 6 (13.6) 20 (45.5)
Unknown 2 (4.5) 1 (2.3)
Data are n (%).
RECIST, Response Evaluation Criteria in Solid Tumor.
Table 3. Postdiscontinuation treatments
Standardizedmedication name Reported name
No. of
patients
Cabozantinib Cabozantinib 1
Cabozantinib or placebo 1
Carboplatin Carboplatin 1
Docetaxel Docetaxel 1
Gemcitabine w/oxaliplatin Gemox (gemcitabine 1
oxaliplatin)
1
Gemcitabine and oxaliplatin 1
Gemox (gemcitabine 1
oxaliplatin)
2
Investigational drug Investigational drug 1
Regorafenib Regorafenib 2
Sorafenib Sorafenib 4
Tivantinib Tivantinib 1
All other therapeutic products Experimental
immunotherapy treatment
1
No. of patients with at least one
postdiscontinuation therapy
12
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subsequently received galunisertib at the higher dose of 150 mg
b.i.d. At the cutoff date for this analysis of November 21, 2017, 4
patients remained on treatment and 6 patients were in survival
follow-up. The complete patient disposition is shown in Figure S2
(see Supplementary Digital Content 2, http://links.lww.com/
CTG/A56). The demographic and baseline disease characteristics
of the patient population are shown in Table 1. Approximately
50% of patients entered the study less than 6 months from initial
HCC diagnosis (range: 0.7–141 months).
Nodose-limiting or significant toxicitieswere observed during
the lead-in period. The combination dose of galunisertib, when
administered with sorafenib 400 mg orally b.i.d., was defined as
150mgorally b.i.d. for 14 days, followed by 14 days off, in a 28-day
cycle.
Table 4. Most frequent TEAEs possibly related to study drug (>10% of patients)
Preferred terma
Galunisertib 160mg/d1 sorafenib 400mg/d, N53 Galunisertib 300 mg/d1 sorafenib 400 mg/d, N5 44
Grade 1b Grade 2 Grade 3 Grade 4 All Grade 1 Grade 2 Grade 3 Grade 4 All
Palmar-plantar erythrodysesthesia syndrome 0 1 (33.3) 0 0 1 (33.3) 7 (15.9) 8 (18.2) 10 (22.7) 0 25 (56.8)
Diarrhea 1 (33.3) 0 0 0 1 (33.3) 13 (29.5) 3 (6.8) 3 (6.8) 0 19 (43.2)
Pruritis 1 (33.3) 0 0 0 1 (33.3) 7 (15.9) 4 (9.1) 0 0 11 (25.0)
Weight decreased 1 (33.3) 2 (66.7) 0 0 3 (100) 3 (6.8) 5 (11.4) 2 (4.5) 0 10 (22.7)
Fatigue 1 (33.3) 1 (33.3) 0 0 2 (66.7) 4 (9.1) 3 (6.8) 2 (4.5) 0 9 (20.5)
Anemia 0 0 1 (33.3) 0 1 (33.3) 1 (2.3) 3 (6.8) 5 (11.4) 0 9 (20.5)
Alopecia 0 0 0 0 0 7 (15.9) 0 1 (2.3) 0 8 (18.2)
Nausea 0 1 (33.3) 0 0 1 (33.3) 4 (9.1) 4 (9.1) 0 0 8 (18.2)
Myalgia 0 0 0 0 0 5 (11.4) 2 (4.5) 1 (2.3) 0 8 (18.2)
Rash 1 (33.3) 0 0 0 1 (33.3) 5 (11.4) 3 (6.8) 0 0 8 (18.2)
Decreased appetite 2 (66.7) 0 0 0 2 (66.7) 3 (6.8) 3 (6.8) 0 0 6 (13.6)
Abdominal pain 1 (33.3) 0 0 0 1 (33.3) 3 (6.8) 2 (4.5) 0 0 5 (11.4)
Arthralgia 0 0 0 0 0 3 (6.8) 2 (4.5) 0 0 5 (11.4)
Stomatitis 0 0 0 0 0 3 (6.8) 2 (4.5) 0 0 5 (11.4)
Thrombocytopenia 0 0 0 0 0 1 (2.3) 3 (6.8) 1 (2.3) 0 5 (11.4)
Dry skin 0 0 0 0 0 5 (11.4) 0 0 0 5 (11.4)
Asthenia 0 0 0 0 0 2 (4.5) 2 (4.5) 1 (2.3) 0 5 (11.4)
Hypertensionc 0 0 0 0 0 0 3 (6.8) 2 (4.5) 0 5 (11.4)
Flatulence 2 (66.7) 0 0 0 2 (66.7) d d d d d
Dry mouth 1 (33.3) 0 0 0 1 (33.3) d d d d d
Erythema multiforme 1 (33.3) 0 0 0 1 (33.3) d d d d d
Fall 1 (33.3) 0 0 0 1 (33.3) d d d d d
Hemoglobin decreased 1 (33.3) 0 0 0 1 (33.3) d d d d d
Pyrexia 1 (33.3) 0 0 0 1 (33.3) d d d d d
Vertigo 1 (33.3) 0 0 0 1 (33.3) d d d d d
Duodenal ulcer 0 1 (33.3) 0 0 1 (33.3) d d d d d
Gastrointestinal hemorrhage 0 0 1 (33.3) 0 1 (33.3) d d d d d
General physical health deterioration 0 0 1 (33.3) 0 1 (33.3) d d d d d
Pulmonary embolism 0 0 1 (33.3) 0 1 (33.3) d d d d d
Rash maculopapular 0 1 (33.3) 0 0 1 (33.3) d d d d d
Renal injury 0 0 0 1 (33.3) 1 (33.3) d d d d d
Second primary malignancy 0 0 1 (33.3) 0 1 (33.3) d d d d d
Upper gastrointestinal hemorrhage 0 0 1 (33.3) 0 1 (33.3) d d d d d
TEAE, treatment emergent adverse event.
aMedDRA, Medical Dictionary for Regulatory Activities.
bCTCAE v4, Common Terminology Criteria for Adverse Events version 4.
cProtocol required adequate blood pressure control at entry.
dOccurred in less than 10% of patients.
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Efficacy
In patients treated with galunisertib at the higher dose of 150 mg
b.i.d., the median TTP by RECIST v1.1 was 4.1 months (95% CI:
2.8, 6.5) (Figure 1a); themedian TTPbymRECISTwas 4.1months
(95%CI: 2.8, 6.5) (Figure 1b); and themedian OS was 18.8months
(95%CI: 14.8, 24.8) (Figure 1c). Partial responses occurred in 4.5%
by RECIST v1.1 assessed by investigators (Table 2).
Twelve patients (25.5%) received at least one post-
discontinuation therapy (Tables 3 and 4). Half of these patients
received chemotherapy, whereas the other half received tar-
geted agents, including regorafenib, sorafenib, tivantinib, and
cabozantinib.
Subgroup analysis
TTP and OS were analyzed by baseline biomarker values: AFP
,400 ng/mL and$400 ng/mL (Figure 2a) and TGF-b1 less than
or greater than/equal to the baseline median (1956 pg/mL)
(Figure 2b). Patients with baseline AFP$ 400 ng/mL or patients
with baseline TGF-b1 $ baseline median (1956 pg/mL) dem-
onstrated trends toward longer TTP. TGF-b1 responders (at least
20% decrease from baseline at any time point) had significantly
longer OS (22.8 vs 12 months, P 5 0.038) (Figure 3). For AFP
responders and nonresponders, OS was 17.9 months and 20.6
months, P5 0.49.
Limited archival tumor samples (n 5 24) were available for
analysis. Because of the limited amount of tissue, a comprehen-
sive evaluation of all targets was not possible, including for gene
expression studies. Immunohistochemistry data were obtained
for expression of TGF-b RII and pSMAD2. Among the 24
patients, 3 patients had tumors positive for TGF-b RII (3/24;
12.5%), and 15 were positive for pSMAD2 (15/24; 62.5%). There
was no correlation between tumor pSMAD2 and circulating
TGF-b1 (R25 0.05). The limited sample size was insufficient for
determination of any statistical relationship between tumor tissue
TGF-b RII or pSMAD2 expression with TTP or OS.
Safety
Most treatment emergent adverse events assessed as at least
possibly related to study drug were of low grade (CTCAE v4
grades 1–3); one patient had a grade 4 renal injury (see Table 4).
The most frequent treatment emergent adverse events of any
grade (% of patients) were palmar-plantar erythrodysesthesia
(56.8%), diarrhea (43.2%), and pruritis (25.0%). Twenty-eight
(59.6%) patients had a serious adverse event; only the serious
adverse event of anemia was reported in.2 patients (7 [14.9%]).
One patient died while on study treatment due to hepatic failure
(considered unrelated to study treatment). Dose reductions in
galunisertib were required in 2 (4.3%) patients, whereas dose
Figure 2. Kaplan-Meier plots of time-to-tumor progression by baseline biomarkers: 150mg b.i.d. cohort. (a) Subgroups by baseline AFP,400 (blue) and
AFP$400 ng/mL (red). (b) Subgroups by baseline TGF-b1,median (blue) and TGF-b1$median (red) (median51956 pg/mL). AFP, alpha fetoprotein;
CI, confidence interval; TGF-b1, tumor growth factor-b.
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reductions in sorafenib were required in 27 (57.4%) patients.
Treatment discontinuation for toxicity occurred in 5 (10.6%)
patients.
Pharmacokinetics
The PK of galunisertib (see Figure S3, a–b, Supplementary Digital
Content 3, http://links.lww.com/CTG/A57) for 80 mg and 150
mg b.i.d. oral doses, coadministered with sorafenib, was similar to
that observed in previous studies of galunisertib treatment as
monotherapy: absorption within 2–3 hours and an elimination
half-life of 8 hours (33). In addition, similar sorafenib plasma
concentrations were observed in combination with galunisertib
(day 14) and in the absence of galunisertib (day 22) (see Figure
S3c, Supplementary Digital Content 3, http://links.lww.com/
CTG/A57).
DISCUSSION
Part C of this phase 2 study tested galunisertib, a small molecule
that selectively inhibits the serine/threonine kinase of the TGF-b
RI, in combinationwith sorafenib in patients with advancedHCC
who had not received prior systemic therapy. In the 150 mg b.i.d.
galunisertib cohort, the median TTP of 4.1 months for the
combination did not exceed the historical TTPwithmonotherapy
sorafenib in similar populations (4,5,11). The median OS of 18.8
months in this cohort was longer than historical outcomes for this
population, however, suggesting that the inhibition of TGF-b
signaling may have delayed the resistance of tumors to
sorafenib (4,11). Since sorafenib has been reported to reduce
regulatory T cells in patient samples and galunisertib has
shown a similar effect in preclinical models (34), the as-
sumption was that both agents would have an additive effect in
removing regulatory T cells associated with immune escape in
HCC. Because there was no control arm and no evaluation of
peripheral regulatory T-cell counts in this study, it cannot be
concluded whether the combination of agents had an additive
effect on improving the immune response in HCC by reducing
peripheral T regulatory cells.
Unlike previous studies of other novel agents in combination
with sorafenib confounded by additive toxicity (35–37), the
combination of sorafenib plus galunisertib showed manageable
toxicity and tolerability, without apparent increase of sorafenib
toxicities, and without impact on the sorafenib PK profile. The
favorable safety profile of galunisertib coupled with its mecha-
nism of TGF-b RI signaling inhibition supports its potential
benefit in other combinations, including an ongoing study in
combination with nivolumab (NCT02423343) based upon pre-
clinical synergistic activity of galunisertib and checkpoint
inhibitors (38).
We monitored plasma TGF-b1 levels at baseline and
during treatment and analyzed its effect on outcomes. Patients
with TGF-b1 levels greater than median at baseline had
a longer TTP than those below the median (not statistically
significant). Patients who were classified as TGF-b1 res-
ponders, with a decline in circulating TGF-b1 on treatment,
Figure 3. Kaplan-Meier plots of time-to-tumor progression (a) and overall survival (b) by TGF-b1 responders (blue,.20% maximum reduction from
baseline) and TGF-b1 nonresponders (red,#20% maximum reduction from baseline). CI, confidence interval; TGF-b1, tumor growth factor-b.
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also demonstrated a trend toward prolonged TTP, although
cut-points for defining response have not been validated.
Furthermore, OSwas significantly longer in TGF-b1 responders
compared to nonresponders (22.8 vs 12 months, P 5 0.038).
These data are consistent with previous findings suggesting
TGF-b1 plasma levels as a marker for response to targeted
therapies (28,39).
We investigated factors that may have contributed to
the OS and found that, as expected, patients receiving addi-
tional treatments after they stopped the experimental treat-
ment (12/47; 25.5%) had a longer median OS (28.8 months)
compared to those who did not receive additional therapies
(35/47; 74.5% and median OS of 16.4 months, log rank
P 5 0.0571).
The promising survival and safety outcomes of the combi-
nation of galunisertib plus sorafenib in this study support further
exploration of TGF-b RI inhibition with galunisertib as a com-
bination strategy with other agents whose activity may be aug-
mented by inhibition of TGF-b signaling, including potential
combination with PD1/PDL1 inhibitors.
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